Document Detail


Insulin plus a sulfonylurea agent for treating type 2 diabetes.
MedLine Citation:
PMID:  1828656     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To review the recent literature on the efficacy of combined insulin and sulfonylurea therapy in patients with type 2 diabetes. DATA SOURCES: Pertinent articles were obtained through an English-language MEDLINE search from 1979 to 1990 and from the references of these articles. STUDY SELECTION: We reviewed the studies in which patients with poorly controlled diabetes received insulin and a sulfonylurea agent and in which insulin treatment alone (usually given in conjunction with a placebo) was compared with insulin plus sulfonylurea therapy. DATA EXTRACTION: Pre- and post-treatment insulin doses, blood glucose levels, glycated hemoglobin values, C-peptide levels, and insulin levels were analyzed. Other data were analyzed separately. RESULTS OF DATA SYNTHESIS: Data from similar trials were compared. Data from concurrent trials were analyzed separately from data derived from cross-over trials. Weighted mean fasting blood glucose levels, glycated hemoglobin levels, insulin dosage, and fasting C-peptide concentrations were determined for insulin plus placebo and insulin plus sulfonylurea agent groups for both types of studies. In concurrent trials, the weighted mean post-treatment glycated hemoglobin level was 11.1% after insulin plus placebo compared with 10.0% after insulin plus a sulfonylurea agent. In cross-over trials, the corresponding values were 10.6% and 9.8%. CONCLUSIONS: Combination therapy with insulin and a sulfonylurea agent only slightly improved glycemic control in patients with type 2 diabetes. When a sulfonylurea agent was used, less exogenous insulin was needed, but fasting serum insulin levels were not different between the treatment groups. Such therapy did not produce nearly normal blood glucose concentrations and therefore should not be used in patients with poorly controlled type 2 diabetes receiving insulin.
Authors:
A L Peters; M B Davidson
Related Documents :
23075146 - Gene expression and release of growth factors during delayed wound healing: a review of...
25250636 - The association between abdominal muscle and type ii diabetes across weight categories ...
23981996 - Knowledge of blood sugar control standard brings the higher attainment rate of hba1c.
23199046 - Inflammatory cytokines as predictive markers for early detection and progression of dia...
94976 - Inhibitors of fibrinolysis in diabetic children, mothers, and their newborn.
11443186 - Longitudinal changes in body fat in african american and caucasian children: influence ...
Publication Detail:
Type:  Journal Article; Meta-Analysis    
Journal Detail:
Title:  Annals of internal medicine     Volume:  115     ISSN:  0003-4819     ISO Abbreviation:  Ann. Intern. Med.     Publication Date:  1991 Jul 
Date Detail:
Created Date:  1991-07-18     Completed Date:  1991-07-18     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0372351     Medline TA:  Ann Intern Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  45-53     Citation Subset:  AIM; IM    
Affiliation:
Cedars-Sinai Medical Center, Los Angeles, California.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Clinical Trials as Topic / methods
Diabetes Mellitus, Type 2 / drug therapy*
Drug Therapy, Combination
Humans
Hypoglycemic Agents / therapeutic use*
Insulin / therapeutic use*
Meta-Analysis as Topic
Research Design
Sulfonylurea Compounds / therapeutic use*
Chemical
Reg. No./Substance:
0/Hypoglycemic Agents; 0/Sulfonylurea Compounds; 11061-68-0/Insulin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Intravascular ultrasound assessment of the renal artery.
Next Document:  Percutaneous transluminal angioplasty in aortic coarctation. The short- and median-term results